Adverse prognostic impact of capsular incision at radical prostatectomy for Japanese men with clinically localized prostate cancer.
OBJECTIVE
The objective of this study was to evaluate the significance of capsular incision (CI) at radical prostatectomy (RP) for men with prostate cancer.


METHODS
This study included 267 men who underwent RP without neoadjuvant therapy and were pathologically diagnosed as having organ-confined disease. CI was defined as exposing benign or malignant glands at the inked margin without documented extraprostatic extension.


RESULTS
Pathological examinations identified CI in 53 RP specimens (19.9%), while CI was not detected in the remaining 214 specimens (80.1%). The locations of CIs in RP specimens from these 53 patients were as follows: 39 (73.6%) at the apex, 11 (20.0%) at the anterior site, 4 (7.5%) at the posterior site and 12 (22.6%) at the bladder neck. The incidence of CI was significantly affected by surgical procedure, preoperative serum PSA and microvenous invasion in RP specimen. During the observation period of this study, biochemical recurrence occurred in 10 (18.9%) of the 53 with CI and 20 (9.3%) of the 214 without CI, and the biochemical recurrence-free survival in patients with CI was significantly poorer than those without CI. Furthermore, of several factors examined, biochemical recurrence was significantly associated with preoperative serum PSA, Gleason score, perineural invasion and capsular incision, among which only preoperative serum PSA appeared to be an independent predictor of biochemical recurrence.


CONCLUSIONS
Despite the lack of independent significance, the presence of CI has an adverse impact on biochemical outcome in patients undergoing RP for clinically localized prostate cancer.
Kumano
Masafumi
M
Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Miyake
Hideaki
H
Muramaki
Mototsugu
M
Kurahashi
Toshifumi
T
Takenaka
Atsushi
A
Fujisawa
Masato
M
D000368:Aged; D006801:Humans; D007564:Japan; D008297:Male; D011379:Prognosis; D011468:Prostatectomy / Q000009:adverse effects* / Q000379:methods*; D011471:Prostatic Neoplasms / Q000601:surgery*; D012189:Retrospective Studies
J Urol. 1996 Apr;155(4):1344-7
8632570
J Clin Oncol. 2003 Feb 1;21(3):401-5
12560426
Int J Urol. 2002 Nov;9(11):635-40
12534908
J Urol. 2002 Feb;167(2 Pt 1):528-34
11792912
BJU Int. 2005 Feb;95(3):281-4
15679778
J Urol. 2000 Jun;163(6):1643-9
10799152
Cancer. 1999 Nov 1;86(9):1775-82
10547551
J Urol. 2003 Dec;170(6 Pt 1):2292-5
14634399
J Urol. 1998 Oct;160(4):1383-5
9751359
Urology. 2006 Aug;68(2):249-52
16904428
J Urol. 2004 Jul;172(1):119-23
15201750
Urol Clin North Am. 1996 Nov;23(4):651-63
8948418
J Urol. 2007 Oct;178(4 Pt 1):1306-10
17698141
Urology. 1996 Jul;48(1):80-90
8693658
J Urol. 1995 Nov;154(5):1818-24
7563355
Semin Urol Oncol. 2000 Feb;18(1):33-7
10719928
Eur Urol. 2006 Aug;50(2):199-201
16624479
Int J Urol. 2008 Aug;15(8):704-7; discussion 708
18462349
Urology. 2001 Nov;58(5):746-51
11711353
Semin Oncol. 1994 Oct;21(5):662-71
7939754